Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Brazil ETF (EWZ) vs Sana Biotechnology Inc (SANA) Price & Performance

Ishares Msci Brazil ETFTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Ishares Msci Brazil ETF vs Sana Biotechnology Inc — how do they compare? Ishares Msci Brazil ETF trades at $35.53, while Sana Biotechnology Inc trades at $3.34 (market cap $987.94M). The key difference: Ishares Msci Brazil ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.

EWZSANA
Sector
Broad Market / FactorHealth
52-Week High
$41.75$5.92
52-Week Low
$26.52$2.68
Market Cap
$987.94M
Enterprise Value
$962.13M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Brazil ETF

EWZ (iShares MSCI Brazil ETF) trades at $35.365, down 1.85% today but maintains a bullish technical outlook with 15 buy signals versus 4 sell signals. The ETF has gained approximately 11% year-to-date, benefiting from Brazil's monetary easing cycle and commodity strength. Recent news highlights Brazil's $9.92 billion Eco Invest auction and export regulation adjustments to meet EU requirements, supporting economic momentum.

The outlook for EWZ remains positive as Brazil's central bank continues rate cuts from historically high levels, creating favorable conditions for equities. Key risks include dependency on commodity prices and potential economic volatility. Analyst sentiment leans bullish with expectations of further upside from monetary policy support and attractive valuations in Brazilian markets.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.45, down 3.36% today, with a bullish technical signal from moving averages and oscillators. The company shows strong analyst support with 82% buy ratings but faces significant financial challenges including negative ROE of -147.41% and consistent quarterly losses. Recent developments include positive clinical data presentations and a strategic collaboration with Mayo Clinic announced in May 2026.

While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial cash burn and negative profitability present significant investment risks. The stock's outlook depends heavily on successful clinical development and future revenue generation from its engineered cell therapies.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ishares Msci Brazil ETF

EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.

Read more on EWZ

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA